Elan Signs $1 Billion Drug

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz

Elan Signs $1 Billion Drug Deal

Elan (NYSE:ELN)
Intraday Stock Chart

Today : Monday 13 May 2013

Click Here for more Elan Charts.

LONDON --Elan Corp. (ELN) Monday said it had reached a $1 billion deal with Theravance Inc. (THRX) for a share in the royalty stream of four respiratory drug programs , as the Irish company fends off approaches from pharmaceutical investor Royalty Pharma.

Dublin-based Elan said the deal, financed in part with a planned bond issue, will give it a 21% share in the potential future royalty payments that Theravance receives from drug company GlaxoSmithKline PLC on Breo Ellipta, Anoro Ellipta, MABA monotherapy and vilanterol monotherapy. Theravance is seeking to bring the drugs to market with GSK if they are cleared by regulators.

Breo Ellipta, a drug for chronic obstructive pulmonary disease, received regulatory clearance from the U.S. Food and Drug Administration last week and the other three drugs are all either awaiting clearance or in late-stage drug trials. Elan Chief Executive Kelly Martin said in an interview he believes all of the drugs are likely to be cleared.

The royalty deal is the latest twist in a struggle between Elan and U.S.-based Royalty Pharma for control of the royalty stream attached to Tysabri, a blockbuster multiple sclerosis drug. Elan sold its 50% stake in Tysabri to Biogen Idec Inc., its long-term partner in developing the drug, for $3.25 billion in February, but it retains a share of future earnings . Elan doesn't have any other revenue-generating drugs other than Tysabri, leaving questions about its future strategic direction and shape.

Royalty Pharma made an initial approach to Elan in February, valuing the company at $6.55 billion, or $11 a share. It later increased its approach to around $7.3 billion, or $12 a share, but so far only 4.3% of Elan's shareholders have indicated they are prepared to accept Royalty Pharma's offer.

"We haven't found any significant shareholder who believes Royalty Pharma has credibility," Mr. Martin said.

A representative for Royalty Pharma didn't immediately respond to a request for comment.

Write to Jessica Hodgson at Jessica.Hodgson@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Deadline Looms for EquipmentShare Investors' Legal Action

Updated Category News Views 3

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 6

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 10

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies

Updated Category News Views 3

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 4

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 4

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 4

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 1

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 1

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
SES Sells to AFC Industries: A Strategic M&A Move

Updated Category News Views 0

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...

Continue Reading

Top 5 Most Recently Viewed Articles

Cardiovalve Targets CE Mark for Advanced Heart Valve Solutions

Updated Category News Views 402

Significant Milestone for Cardiovalve's Heart Valve Programs The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch Recently, Cardiovalve, a prominent player in transcatheter valve replacement technology, successfully completed patient enrollment for the groundbreaking Cardiovalve TARGET study focused on...

Continue Reading
Inflammatix Strengthens Leadership Team with New Executives

Updated Category News Views 190

Inflammatix Expands Leadership Team Inflammatix, a leader in molecular diagnostics, has made significant strides by adding three industry veterans to its executive leadership team. This strategic expansion is aimed at spearheading the commercialization of the company's flagship product, the TriVerity™ Test. The newly appointed executives include Dr. Sam Ajizian as Chief...

Continue Reading
Understanding Bitcoin Treasury Holdings and Market Impacts

Updated Category News Views 160

The Dynamics of Bitcoin and Treasury Companies In recent months, the activity surrounding Bitcoin has captured the financial world's attention, especially with treasury companies increasingly acquiring substantial amounts of BTC. However, despite this significant uptick in investment, the anticipated price escalation has not occurred as expected. Trends in Corporate...

Continue Reading
Trump Promises Legal Action Against Google if Elected

Updated Category News Views 108

Back in 2024, Donald Trump threw down the gauntlet on Google (NASDAQ: GOOGL) during a Truth Social update, claiming he'd go after them legally if he won the presidency. This wasn’t just some offhand comment; it was a calculated move that tied into his broader campaign strategy as he sought to rally his base around claims of media bias. Media Bias or Political Theater?...

Continue Reading
Upcoming Earnings Report Analysis for Asana (NYSE: ASAN)

Updated Category News Views 139

Asana's Earnings Preview Asana (NYSE: ASAN) is set to release its quarterly earnings report soon, generating anticipation among investors. Understanding the key insights prior to the announcement can be vital for making informed investment decisions. Analysts have estimated that the company could report an earnings per share (EPS) of $-0.03. The Market's Expectations...

Continue Reading